<DOC>
	<DOCNO>NCT01190930</DOCNO>
	<brief_summary>This partially randomized phase III trial study different combination risk-adapted chemotherapy regimen side effect compare well work treat young patient newly diagnose standard-risk acute lymphoblastic leukemia B-lineage lymphoblastic lymphoma find tissue organ begin ( localize ) . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving one drug ( combination chemotherapy ) , give drug different dos , give drug different combination may kill cancer cell .</brief_summary>
	<brief_title>Risk-Adapted Chemotherapy Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia Localized B-Lineage Lymphoblastic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : l. To determine maintenance regimen contain weekly oral methotrexate 40 mg/m^2/week result improve disease free survival ( DFS ) compare contain weekly oral methotrexate 20 mg/m^2/week average-risk ( AR ) subset patient standard-risk B-precursor acute lymphoblastic leukemia ( ALL ) . II . To determine whether reduced-pulses maintenance regimen vincristine ( vincristine sulfate ) /dexamethasone pulse deliver every 12 week use without adversely impact DFS compare pulse give every 4 week AR subset patient standard risk B-precursor ALL . III . To confirm patient low-risk ( LR ) subset standard risk B-precursor ALL , base clinical cytogenetic feature minimal residual disease ( MRD ) criterion , attain 5 year DFS least 95 % either P9904 base regimen include 6 course intermediate dose ( 1 g/m^2 24 hour ) methotrexate without alkylating agent anthracyclines ( Arm LR-M ) , outpatient base regimen identical AR patient reduce vincristine/dexamethasone pulse 12 week interval maintenance ( Arm LR-C ) . IV . To provide standardized treatment enhance supportive care child standard-risk ( SR ) Down syndrome-ALL order improve outcome facilitate study biologically clinically unique patient subgroup . V. To improve understand biology localize B-lineage lymphoblastic lymphoma ( B-LLy ) Down syndrome ( DS ) B-LLy obtain biologic data , include fluorescence situ hybridization ( FISH ) recurrent cytogenetic lesion paraffin specimen , bank tissue future research . VI . To describe 5-year EFS overall survival ( OS ) patient Murphy stage I II B-LLy receive modify AR B-ALL therapy . SECONDARY OBJECTIVES : I . To assess burden AR B-ALL therapy measure survey child 's quality life , miss day school/daycare/work child parent , family functioning , parental perception child 's health vulnerability , physical functioning , emotional distress , 1 ) overall different time point end therapy , 2 ) compare child randomize every 4 week vs. every 12 week dexamethasone/vincristine pulse maintenance . ( Closed accrual April 19 , 2013 ) II . To characterize onset , severity , natural history vincristine associate neuropathy physical therapist ( occupational therapist ) child undergo therapy AR B-ALL , 1 ) overall different time point end therapy , 2 ) compare child randomize every 4 week vs. every 12 week dexamethasone/vincristine pulse maintenance . ( Closed accrual March 15 , 2013 ) TERTIARY OBJECTIVES : I . To explore correlation minimal marrow disease ( MMD ) diagnosis outcome patient B-LLy . OUTLINE : All patient receive induction therapy comprise intrathecal ( IT ) cytarabine day 1 ; vincristine sulfate IV day 1 , 8 , 15 , 22 ; dexamethasone orally ( PO ) IV twice daily ( BID ) day 1-28 ; pegaspargase IV 1-2 hour day 4 ; IT methotrexate* day 8 29 . Patients Philadelphia chromosome-positive disease eligible transfer COG-AALL0622 day 15 induction therapy patient high-risk ( HR ) high-risk ( VHR ) disease eligible transfer COG HR VHR trial end induction therapy . Patients standard-risk disease Down syndrome ( DS ) bone marrow minimal residual disease 0.01 % eligible transfer DS stratum HR trial . Patients induction failure ( define M3 [ &gt; 25 % lymphoblast ] day 29 ) may eligible COG VHR-acute lymphoblastic leukemia study . NOTE : *Patients DS also receive oral leucovorin calcium every 12 hour day 10-11 31-32 . STANDARD-RISK WITH DOWN SYNDROME : Consolidation therapy ( 4 week ) : Patients receive vincristine sulfate IV day 1 ; mercaptopurine PO day 1-28 ; IT methotrexate day 1 , 8 , 15 ; leucovorin calcium PO every 12 hour day 3-4 , 10-11 , 17-18 . Interim maintenance I therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 ; IT methotrexate day 31 ; leucovorin calcium PO every 12 hour day 36-34 . Delayed-intensification therapy ( 8 week ) : Patients receive dexamethasone PO IV BID day 1-7 15-21 ; vincristine sulfate IV doxorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 ; pegaspargase IV 1-2 hour day 4 ; cyclophosphamide IV 30-60 minute day 29 ; thioguanine PO day 29-42 ; cytarabine IV 1-15 minute subcutaneously ( SC ) day 29-32 33-39 ; IT methotrexate day 1 29 ; leucovorin calcium PO every 12 hour day 3-4 31-32 . Interim maintenance II therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 ; IT methotrexate day 1 31 ; leucovorin calcium PO every 12 hour day 3-4 33-34 . Maintenance therapy : Patients receive vincristine sulfate IV day 1 ; dexamethasone PO BID day 1-5 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . Courses repeat every 12 week 2 year ( timed start interim maintenance I therapy ) . AVERAGE-RISK : Consolidation therapy ( 4 week ) : Patients receive vincristine sulfate IV day 1 ; mercaptopurine PO day 1-28 ; IT methotrexate day 1 , 8 , 15.Interim maintenance I therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 IT methotrexate day 31 . Delayed intensification therapy ( 8 week ) : Patients receive dexamethasone PO IV BID day 1-7 15-21 ; vincristine sulfate IV doxorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 ; pegaspargase IV 1-2 hour day 4 ; cyclophosphamide IV 30-60 minute day 29 ; thioguanine PO day 29-42 ; cytarabine IV 15-30 minute SC day 29-32 36-39 ; IT methotrexate day 1 29 . Interim maintenance II therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 IT methotrexate day 1 31 . Maintenance therapy : Patients randomize 1 4 maintenance therapy treatment arm . Arm A : Patients receive vincristine sulfate IV day 1 , 29 , 57 ; dexamethasone PO BID day 1-5 , 29-33 , 57-61 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . Arm B : Patients receive vincristine sulfate IV day 1 , 29 , 57 ; dexamethasone PO BID day 1-5 , 29-33 , 57-61 ; higher-dose methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . Arm C : Patients receive vincristine sulfate IV day 1 ; dexamethasone PO BID day 1-5 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . Arm D : Patients receive vincristine sulfate IV day 1 ; dexamethasone PO BID day 1-5 ; higher-dose methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . In arm , maintenance therapy course repeat every 12 week 2 year girls 3 year boys ( timed start interim maintenance I therapy ) . LOW-RISK : Patients randomize 1 2 treatment arm . Arm I ( LR-M ) : Consolidation therapy ( 19 week ) : Beginning one week completion induction therapy , patient receive vincristine sulfate IV day 15 , 22 , 78 , 85 ; methotrexate IV 24 hour IT methotrexate day 8 , 29 , 50 , 71 , 92 , 113 ; leucovorin calcium PO IV day 9-10 , 30-31 , 51-52 , 72-73 , 93-94 , 114-115 ; dexamethasone PO BID IV day 15-21 78-84 ; PO mercaptopurine day 1-133.Maintenance therapy : Patients receive vincristine sulfate IV day 1 8 ; dexamethasone PO BID day 1-7 ; methotrexate* PO day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 , 85 , 92 , 99 , 106 ; mercaptopurine PO day 1-112 . Courses repeat every 16 week . Patients also receive IT methotrexate day 1 85 ( course 1 4 ) , day 57 ( course 2 5 ) , day 29 ( course 3 6 ) . Patients receive course 7 comprise vincristine sulfate IV day 1 8 ; dexamethasone PO BID day 1-7 ; methotrexate PO day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 ; mercaptopurine PO day 1-70 . Treatment continue 2 Â½ year ( timed date diagnosis ) .NOTE : *Patients receive methotrexate PO day receive IT methotrexate . Arm II ( LR-C ) : Consolidation therapy ( 4 week ) : Patients receive vincristine sulfate IV day 1 ; oral mercaptopurine day 1-28 ; IT methotrexate day 1 , 8 , 15 . Interim maintenance I therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 IT methotrexate day 31 . Delayed-intensification therapy ( 8 week ) : Patients receive dexamethasone PO IV BID day 1-7 15-21 ; vincristine sulfate IV doxorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 ; pegaspargase IV 1-2 hour day 4 ; cyclophosphamide IV 30-60 minute day 29 ; thioguanine PO day 29-42 ; cytarabine IV 1-15 minute SC day 29-32 36-39 ; IT methotrexate day 1 29.Interim maintenance II therapy ( 8 week ) : Patients receive vincristine sulfate IV methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 IT methotrexate day 1 31 . Maintenance therapy : Patients receive vincristine sulfate IV day 1 ; dexamethasone PO BID day 1-5 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; mercaptopurine PO day 1-84 ; IT methotrexate day 1 . Courses repeat every 12 week 2 year girls 3 year boys ( timed start interim maintenance I therapy ) . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>BALL patient must enrol AALL08B1 prior treatment enrollment AALL0932 Note : BLLy patient eligible AALL08B1 , enroll directly onto AALL0932 BALL patient must initial white blood cell count &lt; 50,000/uL Patients must newly diagnose National Cancer Institute ( NCI ) Standard Risk BALL BLLy Murphy stag I II ; patient Down syndrome also eligible Note : BLLy patient tissue available flow cytometry , criterion diagnosis analogous BALL ; tissue process mean ( i.e . paraffin block ) , methodology criterion immunophenotypic analysis establish diagnosis BLLy define submit institution accept All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet With exception steroid pretreatment ( define ) administration intrathecal cytarabine , patient must receive prior cytotoxic chemotherapy either current diagnosis BALL BLLy cancer diagnose prior initiation protocol therapy AALL0932 Patients receive prior steroid therapy may eligible AALL0932 Patients central nervous system 3 ( CNS3 ) leukemia CNS status must know prior enrollment ; ( Note : CNS status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ) ; BLLy patient CNS3 disease eligible protocol COG HR ALL protocol ; recommend intrathecal cytarabine administer time diagnostic lumbar puncture ; usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture ; allow prior registration ; systemic chemotherapy must begin within 72 hour first dose intrathecal therapy BALL patient testicular leukemia eligible AALL0932 For BLLy patient follow additional exclusion criterion apply : Tlymphoblastic lymphoma Morphologically unclassifiable lymphoma Absence Bcell Tcell phenotype marker case submit lymphoblastic lymphoma CNS3positive disease testicular involvement M2 ( 5 % 25 % blast ) M3 ( &gt; 25 % blast ) marrow Female patient pregnant ineligible Lactating female eligible unless agree breastfeed infant Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>